How I treat patients with advanced systemic mastocytosis
- PMID: 20855864
- DOI: 10.1182/blood-2010-08-292144
How I treat patients with advanced systemic mastocytosis
Abstract
Advanced systemic mastocytosis (SM) is a rare myeloid neoplasm characterized by uncontrolled accumulation of neoplastic mast cells (MCs) in various organs with consecutive impairment of organ function, drug resistance, and a poor prognosis. Advanced SM may present as smoldering or slowly progressing neoplasm but may also present as rapidly progressing aggressive SM or even as MC leukemia. Approximately half of the patients have an associated hematologic non-MC-lineage disease (SM-AHNMD) or develop an AHNMD over time. Drug resistance may not only result from the KIT mutant D816V that is found in most patients, but also from KIT-independent pro-oncogenic signaling pathways that play a role in disease evolution. In patients with slow progression, advanced SM can often be kept under control for months with interferon-α or 2CdA. By contrast, in rapidly progressing aggressive SM and MC leukemia, even polychemotherapy and hematopoietic stem cell transplantation may fail, which points to the need to develop new drugs and treatment concepts for these patients. In SM-AHNMD, separate treatment plans should be established for the SM component and the AHNMD component of the disease, with recognition that the AHNMD often has to be managed and treated as a secondary and thus a high-risk neoplasm.
Similar articles
-
Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.Hematology Am Soc Hematol Educ Program. 2015;2015:98-105. doi: 10.1182/asheducation-2015.1.98. Hematology Am Soc Hematol Educ Program. 2015. PMID: 26637707 Review.
-
Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.Am J Hematol. 2015 Mar;90(3):250-62. doi: 10.1002/ajh.23931. Am J Hematol. 2015. PMID: 25688753 Review.
-
In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.Exp Hematol. 2010 Sep;38(9):744-55. doi: 10.1016/j.exphem.2010.05.006. Epub 2010 May 27. Exp Hematol. 2010. PMID: 20553795
-
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.Leukemia. 2015 May;29(5):1115-22. doi: 10.1038/leu.2015.4. Epub 2015 Jan 8. Leukemia. 2015. PMID: 25567135
-
Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.Am J Hematol. 2013 Jul;88(7):612-24. doi: 10.1002/ajh.23459. Epub 2013 May 30. Am J Hematol. 2013. PMID: 23720340 Review.
Cited by
-
Rare gastrointestinal presentation of systemic mastocytosis, a case report.Ann Med Surg (Lond). 2022 Jul 13;80:104196. doi: 10.1016/j.amsu.2022.104196. eCollection 2022 Aug. Ann Med Surg (Lond). 2022. PMID: 36045813 Free PMC article.
-
Management of Advanced Systemic Mastocytosis: Clinical Challenges.J Blood Med. 2024 Sep 11;15:421-433. doi: 10.2147/JBM.S366367. eCollection 2024. J Blood Med. 2024. PMID: 39279879 Free PMC article. Review.
-
Diagnosis and treatment of mast cell disorders: practical recommendations.Sao Paulo Med J. 2013;131(4):264-74. doi: 10.1590/1516-3180.2013.1314590. Sao Paulo Med J. 2013. PMID: 24141298 Free PMC article. Review.
-
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.Hemasphere. 2021 Oct 13;5(11):e646. doi: 10.1097/HS9.0000000000000646. eCollection 2021 Nov. Hemasphere. 2021. PMID: 34901755 Free PMC article. Review.
-
Breast Implant Illness May Be Rooted in Mast Cell Activation: A Case-Controlled Retrospective Analysis.Ann Surg Open. 2024 Mar 13;5(1):e398. doi: 10.1097/AS9.0000000000000398. eCollection 2024 Mar. Ann Surg Open. 2024. PMID: 38883946 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources